Posted in ‘Prescription Cancer Drugs’
10 October 2010
Side effects of the quadrivalent human papillomavirus vaccine (Gardasil) have been pretty much what researchers expected, the CDC and FDA reported, although there were enough instances of of fainting and blood clots reported to worry critics.
With more than 23 million doses of the vaccine distributed, most adverse events “were not greater than the background rates compared with other vaccines,” according to Barbara Slade, MD, of the CDC and colleagues.
But statistical analysis suggested that the rates of fainting and blood clots – 8.2 and 0.2 per 100,000 distributed doses — were disproportionately high, Slade and colleagues wrote in the Aug. 18 issue of the Journal of the American Medical Association.
Other adverse events – including 32 reported deaths – were not out of line with events after other vaccines were introduced, Slade and colleagues said.
Read the entire article here.
(Note from SaneVax: No one knows how many of the ‘distributed doses’ have actually been administered. Therefore, the calculated rate of adverse reactions may be much higher than indicated.)